The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination. 1989

B Bennett, and N A Booth, and A Croll, and A A Dawson
Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill.

Three consecutive patients with acute promyelocytic leukaemia who presented with severe haemorrhagic syndromes were studied and the findings contrasted with those of two patients with classical defibrination after electroshock or complicated labour. The leukaemic patients showed no depletion of fibrinogen. There was no evidence of disordered thrombin generation by either intrinsic or extrinsic pathway sufficient to account for their haemorrhage. All, however, showed strikingly enhanced fibrinolytic activity, which could have accounted for bleeding. This fibrinolytic disorder was characterized by free u-PA in the plasma and differed from that seen after classical defibrination, where free t-PA was observed. U-PA was found also in malignant promyelocytes, which may be the source of u-PA activity in the patients' plasma. Bleeding in promyelocytic leukaemia may be primarily a fibrinolytic disorder.

UI MeSH Term Description Entries
D007123 Immunoelectrophoresis, Two-Dimensional Immunoelectrophoresis in which a second electrophoretic transport is performed on the initially separated antigen fragments into an antibody-containing medium in a direction perpendicular to the first electrophoresis. Immunoelectrophoresis, Crossed,Immunoelectrophoresis, 2-D,Immunoelectrophoresis, 2D,2-D Immunoelectrophoresis,2D Immunoelectrophoresis,Crossed Immunoelectrophoresis,Immunoelectrophoresis, 2 D,Immunoelectrophoresis, Two Dimensional,Two-Dimensional Immunoelectrophoresis
D010960 Plasminogen Activators A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. They are concentrated in the lysosomes of most cells and in the vascular endothelium, particularly in the vessels of the microcirculation. Extrinsic Plasminogen Activators,Plasminogen Activator,Uterine-Tissue Plasminogen Activator,Uterine Tissue Plasminogen Activator
D004591 Electrophoresis, Polyacrylamide Gel Electrophoresis in which a polyacrylamide gel is used as the diffusion medium. Polyacrylamide Gel Electrophoresis,SDS-PAGE,Sodium Dodecyl Sulfate-PAGE,Gel Electrophoresis, Polyacrylamide,SDS PAGE,Sodium Dodecyl Sulfate PAGE,Sodium Dodecyl Sulfate-PAGEs
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006470 Hemorrhage Bleeding or escape of blood from a vessel. Bleeding,Hemorrhages
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014568 Urokinase-Type Plasminogen Activator A proteolytic enzyme that converts PLASMINOGEN to FIBRINOLYSIN where the preferential cleavage is between ARGININE and VALINE. It was isolated originally from human URINE, but is found in most tissues of most VERTEBRATES. Plasminogen Activator, Urokinase-Type,U-Plasminogen Activator,Urinary Plasminogen Activator,Urokinase,Abbokinase,Kidney Plasminogen Activator,Renokinase,Single-Chain Urokinase-Type Plasminogen Activator,U-PA,Single Chain Urokinase Type Plasminogen Activator,U Plasminogen Activator,Urokinase Type Plasminogen Activator
D015473 Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION. Leukemia, Myeloid, Acute, M3,Leukemia, Progranulocytic,Myeloid Leukemia, Acute, M3,Progranulocytic Leukemia,Promyelocytic Leukemia, Acute,AML M3,Acute Promyelocytic Leukemia,Leukemia, Acute Promyelocytic,M3 ANLL,ANLL, M3,Acute Promyelocytic Leukemias

Related Publications

B Bennett, and N A Booth, and A Croll, and A A Dawson
January 1991, Nouvelle revue francaise d'hematologie,
B Bennett, and N A Booth, and A Croll, and A A Dawson
June 1984, Australian and New Zealand journal of medicine,
B Bennett, and N A Booth, and A Croll, and A A Dawson
September 2003, Best practice & research. Clinical haematology,
B Bennett, and N A Booth, and A Croll, and A A Dawson
March 2000, British journal of haematology,
B Bennett, and N A Booth, and A Croll, and A A Dawson
January 1970, Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi,
B Bennett, and N A Booth, and A Croll, and A A Dawson
March 1974, British medical journal,
B Bennett, and N A Booth, and A Croll, and A A Dawson
July 1964, The Medical journal of Australia,
B Bennett, and N A Booth, and A Croll, and A A Dawson
July 1992, British journal of haematology,
B Bennett, and N A Booth, and A Croll, and A A Dawson
December 1966, Postgraduate medical journal,
B Bennett, and N A Booth, and A Croll, and A A Dawson
May 2014, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
Copied contents to your clipboard!